| Company Name: |
Angel Pharmatech, Ltd.
|
| Tel: |
17317130613 |
| Email: |
3358272972@qq.com |
| Products Intro: |
Product Name:TRC160334
CAS:1293289-69-6
Purity:98% Package:100mg
|
| Company Name: |
Shanghai Yifei Biotechnology Co. , Ltd.
|
| Tel: |
021-65675885 18964387627 |
| Email: |
customer_service@efebio.com |
| Products Intro: |
Product Name:TRC160334
CAS:1293289-69-6
Purity:95% Package:2mg;5mg;25mg
|
| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
15002134094 |
| Email: |
marketing@targetmol.cn |
| Products Intro: |
Product Name:TRC160334
CAS:1293289-69-6
Package:1removed
|
|
| | Glycine, N-[(7,8,9,10-tetrahydro-2-hydroxy-4-oxo-4H,6H-cyclohepta[4,5]thiazolo[3,2-a]pyrimidin-3-yl)carbonyl]- Basic information |
| Product Name: | Glycine, N-[(7,8,9,10-tetrahydro-2-hydroxy-4-oxo-4H,6H-cyclohepta[4,5]thiazolo[3,2-a]pyrimidin-3-yl)carbonyl]- | | Synonyms: | Glycine, N-[(7,8,9,10-tetrahydro-2-hydroxy-4-oxo-4H,6H-cyclohepta[4,5]thiazolo[3,2-a]pyrimidin-3-yl)carbonyl]-;TRC160334 | | CAS: | 1293289-69-6 | | MF: | C14H15N3O5S | | MW: | 337.35 | | EINECS: | | | Product Categories: | | | Mol File: | 1293289-69-6.mol | ![Glycine, N-[(7,8,9,10-tetrahydro-2-hydroxy-4-oxo-4H,6H-cyclohepta[4,5]thiazolo[3,2-a]pyrimidin-3-yl)carbonyl]- Structure](CAS/20210305/GIF/1293289-69-6.gif) |
| | Glycine, N-[(7,8,9,10-tetrahydro-2-hydroxy-4-oxo-4H,6H-cyclohepta[4,5]thiazolo[3,2-a]pyrimidin-3-yl)carbonyl]- Chemical Properties |
| density | 1.74±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO : 50 mg/mL (148.21 mM; ultrasonic and warming and heat to 60°C) | | form | Solid | | pka | 3.58±0.10(Predicted) | | color | Off-white to light yellow |
| | Glycine, N-[(7,8,9,10-tetrahydro-2-hydroxy-4-oxo-4H,6H-cyclohepta[4,5]thiazolo[3,2-a]pyrimidin-3-yl)carbonyl]- Usage And Synthesis |
| Uses | TRC160334 is a hypoxia-inducible factor (HIF) hydroxylase inhibitor. TRC160334 can be used for the research of ischemia/reperfusion injury[1]. | | in vivo | TRC160334 (0.1 and 0.3 mg/kg; i.p.) significantly reduces serum creatinine and blood urea nitrogen[1].
TRC160334 (0.3 and 0.6 mg/kg; i.p.) shows reducing trends for acute tubular necrosis[1].
TRC160334 significantly reduces the rise in electrolyte excretion dose dependently. Preischemic treatment with TRC160334 results in a pronounced induction of HSP70 in kidneys by 6 hours while postischemic treatment with TRC160334 results in a pronounced induction of HSP70 in kidneys by 12 hours as compared with the respective vehicle control[1]. | Animal Model: | Sprague-Dawley male rats (250–300 g)[1] | | Dosage: | 0.1 and 0.3 mg/kg | | Administration: | I.p. | | Result: | Significantly reduced serum creatinine and blood urea nitrogen.
|
| Animal Model: | Sprague-Dawley male rats (250–300 g)[1] | | Dosage: | 0.3 and 0.6 mg/kg | | Administration: | I.p. | | Result: | Showed reducing trends for acute tubular necrosis.
|
| | References | [1] Jamadarkhana P, et al. Treatment with a novel hypoxia-inducible factor hydroxylase inhibitor (TRC160334) ameliorates ischemic acute kidney injury. Am J Nephrol. 2012;36(3):208-218. DOI:10.1159/000341870 |
| | Glycine, N-[(7,8,9,10-tetrahydro-2-hydroxy-4-oxo-4H,6H-cyclohepta[4,5]thiazolo[3,2-a]pyrimidin-3-yl)carbonyl]- Preparation Products And Raw materials |
|